Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. - Alcalá C; Gascón F; Pérez-Miralles F; Domínguez JA; Gil-Perotín S; Casanova B (Journal of neurology, 2019)